These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 18607876

  • 1. A phase II study of thalidomide in patients with brain metastases from malignant melanoma.
    Vestermark LW, Larsen S, Lindeløv B, Bastholt L.
    Acta Oncol; 2008; 47(8):1526-30. PubMed ID: 18607876
    [Abstract] [Full Text] [Related]

  • 2. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
    Ott PA, Chang JL, Oratz R, Jones A, Farrell K, Muggia F, Pavlick AC.
    Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
    [Abstract] [Full Text] [Related]

  • 3. A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study.
    Whitehead RP, Moon J, McCachren SS, Hersh EM, Samlowski WE, Beck JT, Tchekmedyian NS, Sondak VK, Southwest Oncology Group.
    Cancer; 2004 Apr 15; 100(8):1699-704. PubMed ID: 15073859
    [Abstract] [Full Text] [Related]

  • 4. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
    Mita MM, Rowinsky EK, Forero L, Eckhart SG, Izbicka E, Weiss GR, Beeram M, Mita AC, de Bono JS, Tolcher AW, Hammond LA, Simmons P, Berg K, Takimoto C, Patnaik A.
    Cancer Chemother Pharmacol; 2007 Feb 15; 59(2):165-74. PubMed ID: 16736151
    [Abstract] [Full Text] [Related]

  • 5. A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
    Markovic SN, Geyer SM, Dawkins F, Sharfman W, Albertini M, Maples W, Fracasso PM, Fitch T, Lorusso P, Adjei AA, Erlichman C.
    Cancer; 2005 Jun 15; 103(12):2584-9. PubMed ID: 15887220
    [Abstract] [Full Text] [Related]

  • 6. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma.
    Lin AY, Brophy N, Fisher GA, So S, Biggs C, Yock TI, Levitt L.
    Cancer; 2005 Jan 01; 103(1):119-25. PubMed ID: 15565573
    [Abstract] [Full Text] [Related]

  • 7. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.
    Hwu WJ, Lis E, Menell JH, Panageas KS, Lamb LA, Merrell J, Williams LJ, Krown SE, Chapman PB, Livingston PO, Wolchok JD, Houghton AN.
    Cancer; 2005 Jun 15; 103(12):2590-7. PubMed ID: 15861414
    [Abstract] [Full Text] [Related]

  • 8. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118).
    Knisely JP, Berkey B, Chakravarti A, Yung AW, Curran WJ, Robins HI, Movsas B, Brachman DG, Henderson RH, Mehta MP.
    Int J Radiat Oncol Biol Phys; 2008 May 01; 71(1):79-86. PubMed ID: 18164847
    [Abstract] [Full Text] [Related]

  • 9. Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF.
    Bottoni U, Bonaccorsi P, Devirgiliis V, Panasiti V, Borroni RG, Trasimeni G, Clerico R, Calvieri S.
    Jpn J Clin Oncol; 2005 Sep 01; 35(9):507-13. PubMed ID: 16120623
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
    McMeekin DS, Sill MW, Darcy KM, Stearns-Kurosawa DJ, Webster K, Waggoner S, Benbrook D.
    Gynecol Oncol; 2007 Sep 01; 106(3):596-603. PubMed ID: 17597196
    [Abstract] [Full Text] [Related]

  • 12. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma.
    Daliani DD, Papandreou CN, Thall PF, Wang X, Perez C, Oliva R, Pagliaro L, Amato R.
    Cancer; 2002 Aug 15; 95(4):758-65. PubMed ID: 12209719
    [Abstract] [Full Text] [Related]

  • 13. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
    Pinter M, Wichlas M, Schmid K, Plank C, Müller C, Wrba F, Peck-Radosavljevic M.
    Eur J Gastroenterol Hepatol; 2008 Oct 15; 20(10):1012-9. PubMed ID: 18787470
    [Abstract] [Full Text] [Related]

  • 14. Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases.
    Powell S, Dudek AZ.
    Anticancer Res; 2009 Oct 15; 29(10):4189-93. PubMed ID: 19846971
    [Abstract] [Full Text] [Related]

  • 15. Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
    Eisen T, Trefzer U, Hamilton A, Hersey P, Millward M, Knight RD, Jungnelius JU, Glaspy J.
    Cancer; 2010 Jan 01; 116(1):146-54. PubMed ID: 19862820
    [Abstract] [Full Text] [Related]

  • 16. Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma.
    Glaspy J, Atkins MB, Richards JM, Agarwala SS, O'Day S, Knight RD, Jungnelius JU, Bedikian AY.
    Cancer; 2009 Nov 15; 115(22):5228-36. PubMed ID: 19728370
    [Abstract] [Full Text] [Related]

  • 17. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
    Ridolfi L, Fiorentini G, Guida M, Michiara M, Freschi A, Aitini E, Ballardini M, Bichisao E, Ridolfi R, Italian Melanoma Intergroup.
    Melanoma Res; 2009 Apr 15; 19(2):100-5. PubMed ID: 19262411
    [Abstract] [Full Text] [Related]

  • 18. Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma.
    Eisen T, Thomas J, Miller WH, Gore M, Wolter P, Kavan P, Martín JA, Lardelli P.
    Melanoma Res; 2009 Jun 15; 19(3):185-92. PubMed ID: 19436178
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma.
    Chan JK, Manuel MR, Ciaravino G, Cheung MK, Husain A, Teng NN.
    Gynecol Oncol; 2006 Dec 15; 103(3):919-23. PubMed ID: 16828852
    [Abstract] [Full Text] [Related]

  • 20. A phase 1 study of granulocyte macrophage colony-stimulating factor (sargramostim) and escalating doses of thalidomide in patients with high-risk malignant melanoma.
    Lutzky J, Weber R, Nunez Y, Gillett M, Spitler L.
    J Immunother; 2009 Jan 15; 32(1):79-85. PubMed ID: 19307996
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.